39 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
the homing and retention of hematopoietic stem cells, or HSCs, in the bone marrow, and also mediates tumor progression, angiogenesis (growth of new blood
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
. In addition, retention of capable sales personnel may be more difficult as we focus on a single product offering and we must retain our sales force in order … , access to capital and employee retention. Such ESG matters may also impact our third-party contract manufacturers and other third parties on which we
6-K
EX-99
BLRX
Bioline Rx Ltd
15 Sep 22
Current report (foreign)
8:39am
), pledge, lien, hypothecation, assignment by way of security or otherwise, trust arrangement, title retention or encumbrance or enforceable right of a third
6-K
EX-99
BLRX
Bioline Rx Ltd
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
Components of Compensation
A-7
2.6.
Motivation and Retention
A-7
Corporate Governance
A-8
3.1.
Compensation Committee Membership and Duties
A-8
3.2 … for a balance between creating incentives which support long-term company goals and retention targets. On the basis of periodic benchmarking, we aim
6-K
EX-99
or8nhcxumilcu
13 Oct 21
BioLineRx Announces Positive Results from
8:37am
424B5
m6iwuv0zt9m29 6jd
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
itkz42 u27c8n
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
w7dzi80rvvry4m bn
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
izorp3ab1xzr
31 Dec 20
Prospectus supplement for primary offering
4:31pm
424B5
yqxvtoscd
13 Nov 20
Prospectus supplement for primary offering
4:31pm
424B5
6q0l9a3sogv mv8
25 Sep 20
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
39exy5n3refmz5b22fm
19 Aug 20
2020 Annual General Meeting of Shareholders
4:34pm
6-K
EX-99
0o4f2u1b3n7bi99lv
6 Aug 20
BioLineRx Reports Second Quarter 2020 Financial Results
7:47am
424B5
bc99ymjvi
3 Jun 20
Prospectus supplement for primary offering
8:33am
424B5
e79ezik a2mzx
28 May 20
Prospectus supplement for primary offering
12:00pm
6-K
EX-99
r0be408a zau0s
20 May 20
BioLineRx Reports First Quarter 2020 Financial Results
7:00am